NewsMeter

Tango Therapeutics expands at-the-market program to $400 million, retiring prior $100 million shelf

8/12/2026

$400,000,000 is the new authorized ceiling on Tango Therapeutics' (TNGX) at-the-market equity program, disclosed in an 8-K filed with the SEC on August 11, 2026.

That figure absorbs the $35,610,434 still unsold under the prior $100 million program, which the company formally terminated the same day.

Net incremental authorization above the original shelf: approximately $364,389,566.

What the prior program drew The first prospectus supplement, filed November 21, 2025 under a Sales Agreement with Leerink Partners LLC, authorized up to $100,000,000 in common stock sales.